Quality of Life for Patients With Advanced Renal Cell Carcinoma During Treatment on Nivolumab Plus Cabozantinib or Sunitinib
Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, explained what patients with aRCC who were given either nivolumab plus cabozantinib or sunitinib reported in regard to their quality of life during treatment.
Pharmacy Times interviewed Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, on her presentation at the 2021 ASCO Annual Meeting on the phase 3 CheckMate 9ER trial assessing nivolumab plus cabozantinib versus sunitinib for advanced renal cell carcinoma (aRCC).
During this discussion, Apolo explained what patients with aRCC who were given either nivolumab plus cabozantinib or sunitinib reported during the phase 3 trial in regard to their quality of life during treatment.
